To identify the right combination of your lead compound with standards of care or new drugs, Oncolines offers three different synergy platforms. The SynergyScreen™ is a high-throughput screen in which your novel drug will be screened against an exemplar library of 42 selected reference anti-cancer agents. This unbiased approach helps you with exploring possible synergistic drug groups of your lead compound. Once you have an idea about the synergistic partners of your drug, synergistic effects can be confirmed in either the SynergyFinder™ or the combination matrix. In SynergyFinder™, equipotent mixtures of two (or more) drugs are tested in three fixed ratios (1:1, 4:1 and 1:4) based on IC50 values. Synergy is evaluated by curve shift analysis and calculation of the Combination Index (CI). In the combination matrix, two compounds are combined in six points dilution range. Synergy is evaluated by calculating the Bliss score. Learn more about the different platforms on the platform specific pages.